­

About admin

This author has not yet filled in any details.
So far admin has created 64 blog entries.

OncBioMune Announces Cancer Vaccine Poster Presentation at the 2017 American Association for Cancer Research Meeting

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel [...]

Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials

BATON ROUGE, LA--(January 26, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

Departments of Urology and Oncology Approve Protocol for OncBioMune’s Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico

OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Submitting Clinical Trial of World’s First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute

BATON ROUGE, LA--(January 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

Patients Pre-Screened for OncBioMune Pharmaceuticals Phase 2/3 Trial of ProscaVax for Prostate Cancer

BATON ROUGE, LA--(December 28, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel [...]

OncBioMune and the Clinical Trial Investigators Have Agreed Upon the Protocol for Their Phase 2 Trial of Novel Vaccine for Early Stage Prostate Cancer

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and [...]

OncBioMune Provides Update on Acquisition of Vitel Laboratorios

BATON ROUGE, LA--(December 07, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the [...]

OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition

BATON ROUGE, LA--(November 11, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

OncBioMune Signs Term Sheet to Acquire Vitel Laboratorios, S.A. de C.V.

BATON ROUGE, LA--(November 03, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the [...]